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Circulating concentration of FGF-23 increases as renal function
declines in patients with chronic kidney disease, but does not
change in response to variation in phosphate intake in healthy
volunteers.
Background. Hyperphosphatemia is a risk factor for the de-
velopment of several different complications of chronic kidney
disease (CKD), including secondary hyperparathyroidism and
cardiovascular complications, due to the formation of calcium-
phosphate deposits. Fibroblast growth factor-23 (FGF-23) is
a recently discovered protein that is mutated in autosomal-
dominant hypophosphatemic rickets, an inherited phosphate
wasting disorder, and it may represent a novel hormonal regu-
lator of phosphate homeostasis. We therefore hypothesized that
FGF-23 levels may be altered in hyperphosphatemia associated
with renal failure and that its concentration changes in response
to different levels of phosphate intake.
Methods. Using a two-site enzyme-linked immunosorbent
assay (ELISA) detecting the C-terminal portion of FGF-23,
serum concentration was measured in 20 patients with differ-
ent stages of renal failure (creatinine range 155 to 724 lmol/L),
in 33 patients with end-stage renal disease (ESRD) on dialysis
treatment, and in 30 patients with functioning renal grafts. Fur-
thermore, six healthy males were given oral phosphate binders
in combination with low dietary phosphate intake for 2 days fol-
lowed by 3 days of repletion with inorganic phosphate. FGF-23
levels were determined at multiple time points.
Results. FGF-23 serum levels were significantly elevated in
CKD with a strong correlation between serum creatinine and
FGF-23 concentration. Independent correlations were also seen
between FGF-23 and phosphate, calcium, parathyroid hormone
(PTH), and 1,25(OH)2D3. No changes in serum FGF-23 levels
were observed in volunteers following ingestion of oral phos-
phate binders/low dietary phosphate intake, which led to a de-
cline in phosphate excretion or during the subsequent repletion
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with inorganic phosphate through oral phosphate and a normal
diet.
Conclusion. Circulating FGF-23 was significantly elevated in
patients with CKD and its concentration correlated with renal
creatinine clearance. In healthy volunteers, FGF-23 levels did
not change after phosphate deprivation or phosphate loading.
Patients with chronic kidney disease (CKD) show im-
paired renal excretion of phosphate that leads to sig-
nificant hyperphosphatemia [1]. Hyperphosphatemia is
an important risk factor for the development of sev-
eral complications of CKD, including formation of ec-
topic calcifications, cardiovascular disease, and secondary
hyperparathyroidism [2]. Consequently, dietary phos-
phate restriction and treatment with oral phosphate
binders are parts of the standard treatment regimen in
these patients [1, 3].
Autosomal-dominant hypophosphatemic rickets,
oncogenic osteomalacia, and X-linked hypophos-
phatemia are phosphate-wasting disorders that share
similar clinical and biochemical characteristics, including
low serum phosphate levels due to increased renal
phosphate clearance and inappropriately low 1,25
dihydroxyvitamin D3 [1,25(OH)2D3] levels [4]. Recent
findings suggest that fibroblast growth factor-23
(FGF-23), the protein mutated in autosomal-dominant
hypophosphatemic rickets, may be involved in the patho-
genesis of all three disorders. In autosomal-dominant
hypophosphatemic rickets, three different mutations
were identified at position 176 or 179 of full-length
FGF-23. These mutations are thought to inhibit inac-
tivation of biologically active FGF-23 by making the
protein resistant to cleavage between position Arg179
and Ser180 and possibly other sites [5].
FGF-23 mRNA and protein are found at high lev-
els in oncogenic osteomalacia tumors. Furthermore, re-
combinant FGF-23 given parenterally to rodents or
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transgenic expression of this growth factor leads to
hypophosphatemia, while ablation of the FGF-23 gene
in mice results in significant hyperphosphatemia [6–8].
Based on these studies, it was therefore postulated that
this growth factor causes, directly or indirectly, renal
phosphate wasting [9, 10]. Recently, we developed a
two-site enzyme-linked immunosorbent assay (ELISA)
detecting the C-terminal portion of human FGF-23 pro-
tein [11]. Using this ELISA, we demonstrated that FGF-
23 levels are readily detectable in healthy individuals.
Furthermore, FGF-23 concentrations were markedly in-
creased in most patients with oncogenic osteomalacia and
returned to within, or close to, the normal range after sur-
gical removal of the tumors [11]. In a significant number
of patients with X-linked hypophosphatemia, circulating
levels of FGF-23 were also found to be increased [11].
To further explore whether FGF-23 might be involved
in the regulation of phosphate homeostasis, we mea-
sured FGF-23 concentrations in patients with renal fail-
ure who often develop severe hyperphosphatemia, if left
untreated, and in normal volunteers on a low phosphate




We consecutively recruited 83 patients with varying
severity of renal failure. The patients were divided into
three groups based on treatment and severity of renal
disease: (1) a predialysis group consisting of 20 patients
(creatinine range 155 to 724 lmol/L), (2) a dialysis group
consisting of 33 patients treated with either continuous
ambulatory peritoneal dialysis (CAPD) (N = 9) or stan-
dard bicarbonate hemodialysis three times a week (N =
24) (creatinine range 500 to 1200 lmol/L), and (3) a trans-
plant group consisting of 30 patients representing a cross-
section of renal transplant patients, all with a varying
degree of renal graft function but generally with a bet-
ter renal function than in the group of predialysis pa-
tients (creatinine range 93 to 364 lmol/L). The patients
in the predialysis group and some patients in the dial-
ysis group, who continued to have some urine output,
were also treated with diuretics. Additional medications
included oral phosphate binders, a phosphate restricted
diet and 1,25(OH)2 vitamin D (Rocaltrol; Roche,
Stockholm, Sweden) or 1,25OH vitamin D (Etalpha;
Leo Pharma, Malmo¨, Sweden). The underlying diseases
in this cohort were glomerulonephritis (37%), type 1 dia-
betes (20%), polycystic kidney disease (12%), interstitial
nephritis, and obstructive nephropathy (10%), hyperten-
sive nephrosclerosis (9%), type 2 diabetes (9%), and oth-
ers (5%). Blood samples were collected during routine
monthly visits to the outpatient clinic (for dialysis patients
at midweek). The time posttransplant at which the blood
was analyzed was 91 ± 14.4 months. Routine biochemical
parameters were analyzed immediately while additional
serum samples were frozen and stored in −70◦C for sub-
sequent analysis of FGF-23 levels.
Phosphate loading/deprivation experiment
Six males between 25 and 45 years of age with no
known health problems and no medication were selected
for this study. Blood samples were collected at 8:00 a.m.,
12:00 a.m., 4:00 p.m., and 8:00 p.m. daily for 6 days. All
morning samples were fasting samples. Day 1 contained
no restrictions or medications. Days 2 and 3 contained
a standardized diet with 2900 kcal per day and a total
phosphate intake of approximately 870 mg per day. For
this purpose a liquid diet specially prepared for patients
with renal failure was used (Nepro) (Abbott Nutrition,
Stockholm, Sweden). Additionally, four tablets of phos-
phate binder (Renagel 403 mg/tablet) (Genzyme,
Cambridge, MA, USA) were taken three times a day.
Days 4 to 6 contained a normal diet supplemented with
600 mg of inorganic phosphate four times a day. The study
was approved by the local ethics committee (approval
number 01-449).
Biochemical analyses
Serum and urine FGF-23 levels were measured, ac-
cording to the manufacturer’s instructions, using the
C-terminal human FGF-23 ELISA (Immutopics, San
Juan Capistrano, CA, USA). This ELISA was developed
using an affinity-purified antibody raised against [Tyr-
223] FGF-23(206–222) amide as capture antibody and an
affinity-purified biotinylated antibody against [Tyr-224]
FGF-23(225–244) amide as detection antibody; recombi-
nant human FGF-23 generated by transfected SF9 cells
was used as standard; the assay sensitivity was 3.0 RU/mL
(normal range 0 to 157 RU/mL). This ELISA has been
previously described in detail [11]. Dilutions of serum
samples were performed in sample diluent (i.e., zero stan-
dard) provided by the manufacturer. For CKD patients,
serum 1,25(OH)2D3 (normal range 20 to 60 ng/L) lev-
els were analyzed by Silab, Malmo¨, Sweden using liquid
chromatography and a competitive radioreceptor assay
from Incstar Corp., Stillwater, MN, USA, respectively.
Intact parathyroid hormone (PTH) was measured by im-
munoradiometric assay (IRMA) (Nichols Institute, San
Juan Capistrano, CA, USA) (normal range 10 to 65 ng/L)
at Uppsala University Hospital. For the healthy volun-
teers, 1,25(OH)2D3 was measured with gamma-B 1,25-
(OH)2-dihydroxy vitamin D kit (IDS, Boldon, England)
and full-length PTH with Elecsys PTH kit (Roche Di-
agnostics, Mannheim, Germany) (normal range 10 to
60 ng/L) at Uppsala University Hospital. Calcium (nor-
mal range 2.20 to 2.60 mmol/L), albumin (normal range 40
to 51 g/L), phosphate (normal range 0.74 to 1.54 mmol/L),
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Fig. 1. The serum values of the three
separate groups. (A) Creatinine (umol/L).
(B) Fibroblast growth factor-23 (FGF-23)
(RU/mL). Note that scales are logarith-
mic. (C) Phosphate (mmol/L). (D) Calcium
(mmol/L). (E) Parathyroid hormone (PTH)
(ng/L). (F) 1,25(OH)2D3 (ng/L). Abbrevia-
tions are: D, dialysis group; PD, predialysis
group; T, transplant group. The boxes repre-
sent the mean ± SEM and the vertical lines the
maximum and minimum values in the popu-
lation measured.
and creatinine (normal range 69 to 113 lmol/L) were
measured by routine methods at the department of clin-
ical chemistry at Uppsala University hospital.
Western blot analysis
A total of 200 lL of urine or serum from dialysis pa-
tients and healthy volunteers were immunoprecipitated
with 20 lL of a rabbit antibody directed against human
[Tyr-224] FGF-23(225–244) amide (the antibody has been
previously described [10]) and incubated at 4◦C with end-
over-end rotation overnight. Then, 200 lL of protein
A sepharose (Pharmacia Amersham, Uppsala, Sweden)
was added and incubated for 30 minutes at room tem-
perature. The samples were spun and rinsed twice with
Tris-HCl buffer (pH 8.0) containing NaCl (150 mmol/L
final concentration) and 0.01% NaN3. Twenty micro-
liters of the solution were then mixed with 20 lL sodium
dodecyl sulfate (SDS) loading buffer for electrophore-
ses through 15% SDS-polyacrylamide gel electrophoresis
(PAGE) minigels (Bio-Rad, Hercules, CA, USA). Sub-
sequent Western blot analyses were performed accord-
ing to standard procedures using the rabbit anti-[Tyr-223]
FGF-23(206–222) amide or rabbit anti-[Tyr-224] FGF-
23(225–244) amide as primary antibody as earlier
described [10] (1 mg/mL; dilution 1:2000), followed by in-
cubation with a horse radish peroxidase (HRP)-coupled
goat antirabbit antibody (Dako, Dakopatt AB, A¨lvsjo¨,
Sweden) [diluted 1:5000 in 5% milk in phosphate-
buffered saline (PBS)] as secondary antibody. Visualiza-
tion of immunoreactive human FGF-23 was performed
by enhanced chemiluminescence (ECL) (Amersham,
Piscataway, NJ, USA).
Statistics
The StatView SE + Graphics software package (Aba-
cus Concepts, Inc., Berkeley, CA, USA) was used for all
statistical analyses. Values below the detection limit for
PTH and 1,25(OH)2D3 were in calculations arbitrarily
assigned the value of half of the difference between the
detection limit and zero. Values are expressed as mean ±
SEM unless otherwise stated.
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Table 1. Relationship between fibroblast growth factor-23 (FGF-23)
and other biochemical parameters
Total population b value R2 value P value
FGF-23
Creatinine 94.1 0.168 =0.0001
Phosphate 44600 0.133 <0.001
Calcium 202000 0.179 <0.0001
Parathyroid hormone 255 0.129 <0.001
1,25(OH)2 vitamin D3 −731 0.006 0.495
Log FGF-23
Creatinine 0.003 0.766 <0.0001
Phosphate 1.213 0.526 <0.0001
Calcium 2.481 0.144 <0.001
Parathyroid hormone 0.003 0.069 <0.05
1,25(OH)2 vitamin D3 −0.063 0.238 <0.0001
A simple regression model with serum values of creatinine, phosphate, calcium,
PTH, and 1,25(OH)2D3 as independent variables versus eigher FGF-23 or log
FGF-23 as dependent variable analyzed in the entire population studied. The log
FGF-23 values assumed a closer approximation to a normal distribution curve
than the FGF-23 values.
RESULTS
The blood chemistry data for patients with CKD dis-
ease grouped according to treatment are presented in
Figure 1. The mean creatinine levels for the predialy-
sis group was 360 ± 170 lmol/L, for the dialysis group
850 ± 190 lmol/L, and for the renal transplant group
150 ± 50 lmol/L (Fig. 1A), reflecting the differences in
renal function between the groups. The corresponding
concentrations of FGF-23, phosphate, calcium, PTH, and
1,25(OH)2D3 are illustrated for each group in Figure 1B
through F. FGF-23 levels were markedly increased in the
dialysis group (59,600 ± 20,500 RU/mL) and, albeit to
a much lesser extent, in the predialysis group (2010 ±
890 RU/mL), while transplanted group showed FGF-
23 concentrations that were close to the normal range
(230 ± 42 RU/mL).
For the entire patient population, the FGF-23 serum
levels correlated with the concentrations of creatinine
(R2 = 0.168; P = 0.0001), phosphate (R2 = 0.133; P <
0.001), calcium (R2 = 0.179; P < 0.0001), and PTH (R2 =
0.129; P < 0.001), when performing a univariate regres-
sion analysis. The data are presented in Table 1. The FGF-
23 values assumed a closer approximation to a standard
distribution curve when transformed to logarithms and
the correlations increased with creatinine (R2 = 0.766;
P < 0.0001) and phosphate (R2 = 0.526; P < 0.0001)
(Fig. 2). The log FGF-23 concentration was also positively
correlated with calcium (R2 = 0.144; P < 0.001) and PTH
(R2 = 0.069; P < 0.05) and negatively with 1,25(OH)2D3
(R2 = 0.238; P < 0.0001).
However, as the three groups were clearly distinguish-
able clinical entities and had different mean FGF-23 val-
ues the three groups were also analyzed separately. A
simple regression model with FGF-23 as the dependent
variable and creatinine, phosphate, calcium, PTH, and
1,25(OH)2D3 as independent variables was used. The









0 250 500 750 1000 1250 1500
Creatinine, µmol/L
Phosphate, mmol/L
0 1 2 3 4
B
A
Fig. 2. The correlation for entire population of 83 patients with varying
stages of renal disease between the log fibroblast growth factor-23 (FGF-
23) serum concentration and creatinine (A) or phosphate (B).
both calcium, PTH, and 1,25(OH)2D3 co-varied with
FGF-23 (P < 0.01). In the predialysis group, phosphate
was the only significant variable correlating with FGF-23
(P < 0.05). The log FGF-23, which even within the groups
more resembled normally distributed values, correlated
to creatinine (P < 0.05), phosphate (P < 0.05), calcium
(P < 0.05), and 1,25(OH)2D3 in the dialysis group. Cor-
relations increased with creatinine (P < 0.001) and phos-
phate (P < 0.01) in the predialysis group compared to
the absolute FGF-23 values in the same group. In the
transplant group, no linear or logarithmic relationship
between FGF-23 and other biochemical parameters was
seen.
To further explore the elevated circulatory levels of
FGF-23 in CKD patients, we performed immunoprecip-
itation followed by Western blotting of serum from one
CKD patient and one healthy volunteer with normal
FGF-23 serum level. In the CKD patient, a protein band
of approximately 32 kD was detected, corresponding to
the expected molecular weight of full-length FGF-23 [6, 9,
10, 12] (Fig. 3). No lower-molecular-weight protein bands
were detected. In the healthy volunteer, only a faint 32 kD
band was seen.
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Table 2. Relationship between fibroblast growth factor-23 (FGF-23)
and other biochemical parameters
Subpopulation b value R2 value P value
Dialysis (FGF-23)
Creatinine 175 0.076 0.120
Phosphate 46000 0.057 0.180
Calcium 317000 0.235 <0.01
Parathyroid hormone 417 0.224 <0.01
1,25(OH)2 vitamin D3 21700 0.269 <0.01
Predialysis (FGF-23)
Creatinine 8.27 0.125 0.126
Phosphate 3560 0.235 <0.05
Calcium 9960 0.160 0.081
Parathyroid hormone 1.97 0.002 0.859
1,25(OH)2 vitamin D3 −112 0.029 0.485
Transplant (FGF-23)
Creatinine 0.434 0.010 0.598
Phosphate 155 0.017 0.497
Calcium 124 0.005 0.720
Parathyroid hormone 0.301 0.012 0.564
1,25(OH)2 vitamin D3 −3.53 0.019 0.480
Dialysis (log FGF-23)
Creatinine 0.002 0.194 <0.05
Phosphate 0.409 0.125 <0.05
Calcium 1.704 0.188 <0.05
Parathyroid hormone 0.002 0.084 0.1016
1,25(OH)2 vitamin D3 0.091 0.131 <0.05
Predialysis (log FGF-23)
Creatinine 0.003 0.487 <0.001
Phosphate 0.754 0.417 <0.01
Calcium 1.165 0.086 0.210
Parathyroid hormone 0.002 0.082 0.2197
1,25(OH)2 vitamin D3 −0.017 0.027 0.5010
Transplant (log FGF-23)
Creatinine 0.002 0.057 0.202
Phosphate 0.211 0.011 0.578
Calcium −0.022 5.207E-5 0.970
Parathyroid hormone 0.001 0.046 0.253
1,25(OH)2 vitamin D3 −0.006 0.017 0.496
A simple regression model with serum values of creatinine, phosphate, cal-
cium, PTH, and 1,25(OH)2 vitamin D3 as independent variables versus FGF-23
or log FGF-23 as dependent variables analyzed in three separate groups: dialysis,
preuremic, and transplant groups. Even in the separate groups, the log FGF-23
values assumed a closer approximation to a normal distribution curve than the
FGF-23 values.
Increased FGF-23 levels in renal failure could be due
to a decreased clearance of FGF-23 by the kidney. We
therefore measured FGF-23 levels in urine from dialy-
sis patients with severe renal disease but residual urine
production. Urine levels of FGF-23 measured in four
dialysis patients ranged from 750 to 10,790 RU/mL,
and serial dilutions of these urine samples ran in par-
allel to the recombinant FGF-23 standard (data not
shown). The presence of FGF-23 immunoreactivity
in urine was confirmed by immunoprecipitation fol-
lowed by Western blot analysis (Fig. 3). Several spe-
cific low-molecular protein bands were readily detected
in urine from CKD patients but only faint bands
were seen when urine from normal volunteers was
immunoprecipitated.
In the second part of our study, we determined FGF-
23 serum levels in six healthy males four times each day
for 6 days. FGF-23 showed no clear circadian variation;
the mean concentration of FGF-23 was 38 ± 8 RU/mL
for the entire group. This value was close to the previous
determined mean concentration of FGF-23 in a group of
141 healthy individuals [11]. Only one subject in our study
showed an average FGF-23 level of 110 U/mL, which is
still within 2 SD the reference range. This individual also
had the highest content of urinary FGF-23 among the
participants (87.6 ± 5.6 RU/mL).
The percentage of inorganic phosphate reabsorbed in
the kidney in relation to total amount of phosphate fil-
trated (%TPR) (normal range 75% to 100%) was used to
determine the efficiency of renal inorganic phosphate re-
absorption. As previously observed [13]%TPR increased
during phosphate deprivation and thus resulted in a
marked reduction in urinary phosphate excretion; dur-
ing phosphate loading %TRP was significantly reduced
from baseline determined during phosphate deprivation
(P < 0.01) when analyzed with the Mann-Whitney test.
Surprisingly, no significant differences in serum or urine
FGF-23 levels were observed during the study (Fig. 4A
and B, respectively). However, serum levels of phos-
phate, PTH, and 1,25(OH)2D3 did not reveal signifi-
cant changes throughout the study (Fig. 4C, E, and F,
respectively).
DISCUSSION
The most striking finding of the present study was the
strong correlation between serum FGF-23 and creatinine
levels in the CKD patient population as a whole. Re-
cent preliminary findings indicated that experimentally
induced renal failure in rats also results in a significant
rise in serum FGF-23 levels [14]. A possible reason for
this could be that FGF-23, or at least its C-terminal frag-
ment, is normally cleared by the kidneys. In support of
this, we show that FGF-23 immunoreactivity is present
in the urine of healthy individuals and that the amounts
are greatly increased in urine from CKD patients with
residual urinary output. In some dialysis patients, ab-
solute serum values of FGF-23 levels were increased,
compared to healthy individuals, by more than a 1000-
fold. The magnitude of this increase also argues for a de-
creased FGF-23 clearance in CKD. The finding that the
healthy volunteer with serum FGF-23 levels at the upper
end of the normal range had the highest urine content of
FGF-23 also suggest renal clearance of FGF-23. In ad-
dition, we found that urine FGF-23 concentration were
tenfold higher in one patient with oncogenic osteomala-
cia and normal renal function than in any of the healthy
volunteers (data not shown). Accumulation of protein
fragments were previously reported for other peptide
hormones and proteins, including PTH and osteopro-
tegerin, and the accumulation of FGF-23 in serum may
thus contribute, through yet unknown mechanisms, to the
skeletal resistance to PTH and bone disease observed in
chronic renal failure [15, 16].
























Fig. 3. Western blot analysis using urine from
a dialysis patient with some residual renal
function (lane 1) and a healthy volunteer (lane
2) after immunoprecipitation with rabbit anti-
[Tyr-224] FGF-23(225–244) amide antibody.
Using the same anti-[Tyr-224] FGF-23(225–
244) amide antibody, a ≈32 kD band and sev-
eral other protein bands of lower molecular
weight were readily detected in urine from
chronic kidney disease (CKD) patients; these
bands were only faint when urine from the
normal volunteer was immunoprecipitated.
When the antibody for detection was preincu-
bated with excessive amount of peptide that
was used for immunization, none of these pro-
tein bands was detected (lane 3). Lanes 4 and
5 displays serum after immunoprecipitation
from a CKD patient and a healthy volunteer,
respectively. Only a ≈32 kD band was de-
tected in both lanes, although much weaker
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Fig. 4. Serum and urine biochemical param-
eters measured during the phosphate depri-
vation/loading experiment in six healthy vol-
unteers marked as P1 to P6. (A) Fibroblast
growth factor-23 (FGF-23) (RU/mL). (B) u-
FGF-23 (RU/mL). (C) Phosphate (mmol/L).
(D) Total amount of phosphate (TPR) (%).
(E) Parathyroid hormone (PTH) (ng/L). (F)
1,25(OH)2D3 (ng/L). FGF-23 and phosphate
were measured at 8:00 a.m., 12:00 a.m.,
4:00 p.m., and 8:00 p.m. throughout the
experiment. u-FGF-23, %TPR, PTH, and
1,25(OH)2D3 were measured every day at
8:00 a.m. The hours 0 to 24 represent the cali-
bration period; hours 24 to 72, the phosphate
deprivation phase; and hours 72 to 144, the
phosphate loading phase. The dashed verti-
cal lines indicate the time at which phosphate
deprivation and phosphate loading, respec-
tively, was started. The hatched areas repre-
sent the adult normal ranges for the different
parameters.
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The elevated levels of FGF-23 in renal failure
could also be due to a direct physiologic response to
hyperphosphatemia. This hypothesis is supported by a
recent finding that hyperphosphatemia induced by di-
etary means causes a marked increase in circulating FGF-
23 levels in rats [17]. Our finding that the predominant
FGF-23 immunoreactivity in serum from a CKD patient
was of the expected full-length molecular weight, suggests
that the increased FGF-23 levels could partly be due to
increased production of intact FGF-23 protein. However,
to determine whether this mechanism contributes to the
increase, it will be necessary to demonstrate increased
FGF-23 production in tissue samples from CKD patients.
Given the fact that FGF-23 induces hypophosphatemia
in vivo [5], we speculated that an external alteration in
phosphate load would regulate the endogenous produc-
tion of FGF-23. In our study, the tubular reabsorption of
phosphate increased significantly during phosphate de-
privation; conversely %TPR decreased following refeed-
ing with phosphate. However, the high doses of inorganic
phosphate given to our volunteers failed to trigger a rise
in FGF-23 despite the significant increase in renal phos-
phate clearance, suggesting that intact FGF-23, or the
fragments that are also measured with this assay, is not di-
rectly responsible for the acute adjustment of phosphate
excretion in the kidney. However, it is possible that long-
term circulating phosphate levels are the most important
factor for the regulation of FGF-23 and no change in
serum phosphate was seen in this study. Alternatively, a
long half-life of the FGF-23 protein could obscure the
effects of acute manipulations. However, recently pub-
lished data suggest a short half-life of intact FGF-23 in
tumor-induced osteomalacia, which does not support the
latter hypothesis [12]. Another reason for not detecting
changes in FGF-23 levels could be the use of an ELISA
that only recognizes the C-terminal portion of FGF-23
and not exclusively the full-length protein. It has been
reported that only the full-length protein is capable of in-
ducing hypophosphatemia in vivo [5] and it is therefore
possible that the active protein is indeed responsible for
the change in phosphate reabsorption but that an excess
of degradation products masks the effect. However, our
finding, which is in agreement with previous reports [12]
that biologic full-length FGF-23 constitutes the main por-
tion of circulating FGF-23 in healthy individuals, argues
against this hypothesis.
We also measured FGF-23 levels in 24-hour urine
collection samples. These samples contained detectable
levels of FGF-23 and there was no change in urine concen-
trations during the different phases of phosphate loading.
Given that FGF-23 normally appears to be cleared by
the kidneys and that its half-life is short one could ex-
pect to find an increased urinary concentration of intact
or fragment(s) of FGF-23 if the endogenous production
increased during phosphate loading. As this was not the
case, our data support the contention that FGF-23 may
not be regulated by acute changes in blood phosphate
concentration.
In an unpublished report where healthy volunteers
were placed on a high phosphate intake for 2 weeks,
a small but significant increase in C-terminal FGF-23
levels was detected [19]. In our study, four of six vol-
unteers showed their highest serum and urine FGF-23
levels during the high phosphate intake phase. This sug-
gests that FGF-23 serum levels indeed will respond to
external phosphate alterations, but that the time course
for phosphate-induced changes in FGF-23 concentration
is different from that chosen for our experiments and that
more chronic changes in dietary phosphate are required
to influence serum FGF-23 levels. Furthermore, it is also
possible that patients with renal failure may be more sus-
ceptible to changes in FGF-23 in response to dietary phos-
phate than the healthy subjects investigated in this study.
Thus it appears possible that short-term changes in phos-
phate intake do not lead to readily detectable alterations
in FGF-23 serum concentration, but that in long-term
hyperphosphatemia, as is often the case in patients with
CKD, the FGF-23 production might be increased. Such a
hypothesis would imply that FGF-23 is not the hormonal
mechanism responsible for the rapid adjustment of re-
nal phosphate clearance in response to change in dietary
intake of phosphate.
CONCLUSION
Circulating levels of FGF-23 protein are increased in
patients with impaired renal function, but in this study
no regulation of FGF-23 was observed after short-term
changes in dietary phosphate intake. However, these pre-
liminary findings will require additional studies in the fu-
ture, including measurement of intact FGF-23 when such
an assay becomes available.
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